Enoxacin

Mechanism of action

Quinolones and fluoroquinolones are bactericidal drugs, eradicating bacteria by interfering with DNA replication. Like other fluoroquinolones, enoxacin functions by inhibiting bacterial DNA gyrase and topoisomerase IV. The inhibition of these enzymes prevents bacterial DNA replication, transcription, repair and recombination. Enoxacin inhibits the expression of the microRNA mir-34-5p, leading to an increase in the lifespan of the nematode C. elegans. Enoxacin is active against many Gram-positive bacteria.Examples of Gram-positive bacteria include: Staphylococcus aureus, Staphylococcus epidermidis, Clostridium perfringens. The quinolone is also active against Gram-negative bacteria.Gram-negative bacteria include: Acinetobacter, Citrobacter, Campylobacter, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Serratia marcescens, Pseudomonas aeruginosa, Proteus mirabilis, Proteus vulgaris, Salmonella, Shigella flexneri.

Pharmacokinetics

After oral administration enoxacin is rapidly and well absorbed from the gastrointestinal tract. The antibiotic is widely distributed throughout the body and in the different biological tissues. Tissue concentrations often exceed serum concentrations. The binding of enoxacin to serum proteins is 35 to 40%. The serum elimination half-life, in subjects with normal renal function, is approximately 6 hours. Approximately 60% of an orally administered dose is excreted in the urine as unchanged drug within 24 hours. A small amount of a dose of drug administered is excreted in the bile. High concentrations of the fluoroquinolone are reached in the urinary tract and this fact ensures an antibacterial effect continued over time, particularly in this district.

Medical uses

Enoxacin can be used to treat a wide variety of infections, particularly gastroenteritis including infectious diarrhea, respiratory tract infections, gonorrhea and urinary tract infections.

Adverse effects

Enoxacin, like other fluoroquinolones, is known to trigger seizures or lower the seizure threshold. The compound should not be administered to patients with epilepsy or a personal history of previous convulsive attacks as it may promote the onset of these disorders.

Contraindications

Enoxacin is contraindicated in subjects with a history of hypersensitivity to the substance or any other member of the quinolone class, or any component of the medicine. Enoxacin, like other fluoroquinolones, can cause degenerative changes in weightbearing joints of young animals. The compound should only be used in children when the expected benefits are outweigh the risks.

Interactions

• Fenbufen: co-administration with some quinolones, including enoxacin may increase the risk of seizures. For this reason, concomitant administration of fenbufen and the quinolone should be avoided, as a precaution.
• Theophylline: in patients treated concurrently with theophylline and enoxacin, concentrations of the methylxanthine in plasma arise due to a reduced metabolic clearance of theophylline.
• Ranitidine, sucralfate, antacids containing magnesium or aluminium, supplements containing calcium, iron, or zinc: co-administration with these substances can lead to therapeutic failure of the antibiotic due to decreased absorption by the intestinal tract. For example, magnesium or aluminium antacids turn enoxacin into insoluble salts that are not readily absorbed by the gastroenteric tract.

Notes

References

References

1. (July 2006). "Quinolones for uncomplicated acute cystitis in women". The Cochrane Database of Systematic Reviews.
2. (December 1991). "Recent developments in the treatment of sexually transmitted diseases". The American Journal of Medicine.
3. (June 2022). "The New Face of a Well-Known Antibiotic: A Review of the Anticancer Activity of Enoxacin and Its Derivatives". Cancers.
4. (April 1993). "Mechanism of action of quinolones against Escherichia coli DNA gyrase". Antimicrobial Agents and Chemotherapy.
5. (October 1985). "The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro". Antimicrobial Agents and Chemotherapy.
6. (September 2018). "Enoxacin extends lifespan of C. elegans by inhibiting miR-34-5p and promoting mitohormesis". Redox Biology.
7. (November 1983). "In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim". Antimicrobial Agents and Chemotherapy.
8. (March 1984). "In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents". The Journal of Antimicrobial Chemotherapy.
9. (July 1984). "Pharmacokinetics and tissue penetration of enoxacin". Antimicrobial Agents and Chemotherapy.
10. (1986). "The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin". Infection.
11. (1985). "Evaluation of biliary pharmacokinetics of oral enoxacin, a new quinolone antibiotic.".
12. (April 1987). "Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males". Antimicrobial Agents and Chemotherapy.
13. (February 1988). "Enoxacin treatment of urinary tract infections in elderly patients". The Journal of Antimicrobial Chemotherapy.
14. (June 1989). "Single-dose enoxacin compared with 3-day treatment for urinary tract infection". Antimicrobial Agents and Chemotherapy.
15. (July 1993). "Quinolones potentiate cefazolin-induced seizures in DBA/2 mice". Antimicrobial Agents and Chemotherapy.
16. (July 1985). "Convulsions related to enoxacin". Lancet.
17. (June 2003). "Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France". Pediatrics.
18. (September 2006). "The use of systemic fluoroquinolones". Pediatrics.
19. (May 1988). "[A case of convulsion, loss of consciousness and subsequent acute renal failure caused by enoxacin and fenbufen]". Nihon Naika Gakkai Zasshi. The Journal of the Japanese Society of Internal Medicine.
20. (October 1992). "[Effects of drugs on the convulsions induced by the combination of a new quinolone antimicrobial, enoxacin, and a nonsteroidal anti-inflammatory drug, fenbufen, in mice]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica.
21. (April 1998). "Role of nitric oxide in the convulsions following the coadministration of enoxacin with fenbufen in mice". Japanese Journal of Pharmacology.
22. (February 1997). "Circadian variation in enoxacin-induced convulsions in mice coadministered with fenbufen". Japanese Journal of Pharmacology.
23. (July 1984). "Enoxacin raises plasma theophylline concentrations". Lancet.
24. (October 1987). "New synthetic quinolone antibacterial agents and serum concentration of theophylline". Chest.
25. (August 1996). "Structure-related inhibitory effect of antimicrobial enoxacin and derivatives on theophylline metabolism by rat liver microsomes". Antimicrobial Agents and Chemotherapy.
26. (1988). "Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans". European Journal of Clinical Pharmacology.
27. (May 1989). "Inhibition of enoxacin absorption by antacids or ranitidine". Antimicrobial Agents and Chemotherapy.
28. (April 1993). "Effect of oral antacids on disposition of intravenous enoxacin". Antimicrobial Agents and Chemotherapy.
29. (January 1993). "Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin". Journal of Clinical Pharmacology.